Anthropometric and biochemical assessment of schizophrenic patients taking clozapine

• Autor(a) principal: ZORTÉA, Karine
• Data de Publicação: 2023
• Outros Autores: Martins BOCK, Patrícia, Benites MORENO, Dolores, Silva Belmonte de ABREU, Paulo
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista de Nutrição
• Texto Completo: https://periodicos.puc-campinas.edu.br/nutricao/article/view/9521
• topic: Clozapine; Schizophrenia; Obesity; Clozapina; Esquizofrenia; Obesidade

ObjectiveThe objective was to access the overweight/obesity rates and variations of biochemical blood parameters in male schizophrenic outpatients taking antipsychotic medication (clozapine), treated at the Schizophrenia and Dementia First Aid Station of the Clinics Hospital in Porto Alegre. MethodsThis is a cross-sectional study with 40 male outpatients diagnosed with schizophrenia and taking clozapine, from the Clinics Hospital in Porto Alegre. Associations between body mass index, waist circumference, body fat percentage, lipid levels and fasting glucose and medication dosage, diet therapy and clozapine monotherapy were verified. ResultsThere was a rate of 71.8% of overweight/obesity, 76.9% of increased waist circumference and 94.1% of high body fat percentage. More than half of the patients (56.8%) had low density lipoprotein cholesterol levels above normal and 64.1% had high triglycerides. LDL-cholesterol levels increased with increasing clozapine dose (p=0.01). ConclusionPatients on clozapine presented excess weight and significant lipid abnormality, needing frequent monitoring of the biochemical blood parameters and early nutritional intervention to optimize treatment.